Press release
MASH Drugs Market 2026-2033 | Metabolic Dysfunction-Associated Steatohepatitis Therapeutics Market, MASH Drug Discoveries, Tirzepatide & Liver Disease Research
MASH Drugs Market Size 2026
By drug class, GLP-1 receptor agonists dominated the global metabolic dysfunction-associated steatohepatitis (MASH) drugs market, accounting for the highest revenue share of 34.96% in 2025.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?kb
The MASH drugs market continues to advance as pharmaceutical companies strengthen clinical pipelines, expand regulatory activities, and accelerate development of targeted liver disease therapies.
United States: Recent Industry Developments
✅ March 2026: Madrigal Pharmaceuticals expanded commercialization activities for Rezdiffra (resmetirom) across the United States following increasing physician adoption for MASH treatment.
✅ February 2026: Akero Therapeutics advanced late-stage clinical development of efruxifermin targeting fibrosis improvement in patients with metabolic dysfunction-associated steatohepatitis (MASH).
✅ January 2026: Gilead Sciences strengthened research collaborations focused on combination therapies for MASH and liver fibrosis management.
✅ December 2025: 89bio reported positive clinical progress for pegozafermin in MASH treatment programs aimed at improving liver function and metabolic health.
Ready to scale in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?kb
List of Key Players 2026:
Madrigal Pharmaceuticals Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Akero Therapeutics, Inc., 89bio, Inc., Inventiva, Sagimet Biosciences Inc., Viking Therapeutics
Additionally, companies such as CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD and Gilead Sciences, Inc. are enhancing their market position through strategic partnerships, clinical development initiatives, and global expansion efforts.
Key Strategic Growth Forecast Projections 2026:
The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: Madrigal Pharmaceuticals increased commercialization activities for Rezdiffra following expanding physician adoption and growing focus on nonalcoholic steatohepatitis treatment solutions.
✅ April 2026: Novo Nordisk advanced clinical development programs evaluating GLP-1-based therapies for MASH treatment to strengthen its metabolic disease portfolio.
✅ March 2026: Eli Lilly expanded research activities focused on obesity-linked liver disease therapies targeting fibrosis reduction and liver function improvement in MASH patients.
✅ February 2026: Pfizer accelerated development of combination therapies for MASH targeting inflammation, fibrosis, and metabolic dysfunction to improve long-term treatment outcomes.
✅ January 2026: Gilead Sciences strengthened strategic collaborations supporting next-generation MASH drug candidates and precision medicine approaches for chronic liver diseases.
✅ December 2025: Boehringer Ingelheim expanded late-stage clinical trial activities for investigational MASH therapies targeting liver fibrosis and metabolic complications.
✅ November 2025: AstraZeneca increased investment in metabolic and liver disease research programs focused on innovative therapies for steatohepatitis management.
✅ October 2025: Roche advanced biomarker and diagnostic integration initiatives supporting early detection and treatment monitoring in MASH therapeutic development.
How Our Market Research Process Works:
The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• October 2025: Novo Nordisk announced an agreement to acquire Akero Therapeutics to strengthen its Phase 3 MASH drug pipeline centered on efruxifermin.
• September 2025: Gilead Sciences expanded its MASH portfolio through a strategic licensing collaboration focused on next-generation fibrosis-targeting therapies.
• July 2025: Boehringer Ingelheim entered a partnership deal to accelerate development of GLP-1 and glucagon-based MASH combination therapies.
• March 2025: Madrigal Pharmaceuticals explored commercial expansion partnerships following the growing adoption of Rezdiffra for MASH treatment.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company accelerated research initiatives targeting liver inflammation and fibrosis associated with MASH and metabolic liver diseases.
✅ February 2026: Mitsubishi Tanabe Pharma expanded partnerships for development of next-generation therapies addressing nonalcoholic steatohepatitis progression.
✅ January 2026: Eisai Co., Ltd. increased focus on metabolic disorder drug discovery programs supporting innovative treatment approaches for MASH patients.
✅ December 2025: Ono Pharmaceutical collaborated with academic research institutes in Japan to advance therapeutic candidates for fatty liver disease and fibrosis treatment.
Major Segments Opportunity 2026:
By Disease Stage: Intraoral X-ray, Extraoral X-ray, Imaging Software, Others
By Medication: 2D Digital Radiography, 3D CBCT, Optical/impression scanners, Digital sensors, Hybrid Systems
By Route of Administration: Endodontics, Implantology, Orthodontics, Oral & Maxillofacial Surgery, Others
Regional Growth Intelligence for Market:
⇥ North America - Leads the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market due to high prevalence of obesity, diabetes, and increasing clinical adoption of advanced liver disease therapies.
⇥ Europe - Growth is supported by rising awareness of liver health, expanding healthcare expenditure, and ongoing research in metabolic disease treatment.
⇥ Asia-Pacific - Fastest-growing region driven by increasing cases of fatty liver disease, changing dietary habits, and improving access to healthcare services.
⇥ Latin America - Market expansion is influenced by growing incidence of metabolic disorders and increasing focus on chronic disease management.
⇥ Middle East & Africa - Emerging demand supported by rising obesity rates, improving diagnostic capabilities, and expanding healthcare infrastructure.
Request Strategic Market Customization: https://datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?kb
FAQ's:
Q1: What is the current size of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market?
A: The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market was valued at US$ 8.56 Billion in 2025 and is projected to reach US$ 31.76 Billion in 2033
Q2: How rapidly is the Market expanding?
A: The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market is expected to grow at a CAGR of 17.70% during the forecast period 2026 to 2033
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MASH Drugs Market 2026-2033 | Metabolic Dysfunction-Associated Steatohepatitis Therapeutics Market, MASH Drug Discoveries, Tirzepatide & Liver Disease Research here
News-ID: 4518224 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Future of Optical Fiber Monitoring Market | Data Center Connectivity, FTTH Deplo …
DataM Intelligence has unveiled its latest research study "Optical Fiber Monitoring Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry expansion. It also highlights emerging opportunities,…
Why Smart Farming Technologies Are Accelerating Wheeled Tractor Machinery Adopti …
The global Wheeled Tractor Machinery market is witnessing substantial growth as agricultural modernization, rising food demand, and increasing farm mechanization accelerate adoption of advanced farming equipment worldwide. Growing labor shortages in agriculture, expansion of precision farming technologies, and government support for agricultural productivity are driving strong demand for wheeled tractors across developed and emerging economies.
➤ Wheeled tractors remain one of the most essential agricultural machinery categories, supporting a wide range…
Why Connected and Electric Vehicles Are Fueling Growth in the Automotive TPMS Ma …
The global Automotive TPMS (Tire Pressure Monitoring System) market is witnessing strong growth as governments and automakers increasingly prioritize vehicle safety, fuel efficiency, and intelligent automotive systems. Rising implementation of mandatory vehicle safety regulations, growing production of passenger and commercial vehicles, and increasing adoption of connected vehicle technologies are accelerating deployment of TPMS solutions worldwide.
Automotive TPMS technology plays a critical role in monitoring tire pressure levels in real time, helping…
Fraud Detection and Prevention Market Expected to Hit USD 122.86 Billion by 2033 …
DataM Intelligence has released a new research report titled "Fraud Detection and Prevention Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size…
More Releases for MASH
United States Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Set …
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market size reached US$ 2.12 billion in 2025 and is expected to reach US$ 28.45 billion by 2033, growing at a CAGR of 38.2% during the forecast period 2026-2033.
Ready to scale in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/metabolic-dysfunction-associated-steatohepatitis-mash-market?kb
United States: Recent Industry Developments
✅ March 2026: Madrigal Pharmaceuticals accelerated commercialization activities for Rezdiffra (resmetirom) to strengthen…
Key Trends Reshaping the Metabolic Dysfunction-Associated Steatohepatitis (MASH) …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size pertaining to treatments for metabolic dysfunction-associated steatohepatitis (MASH) has witnessed substantial expansion lately, projected to surge from its 2024 valuation of $2 billion euros to $2.59 billion euros by 2025, reflecting a…
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
